10 Best NASDAQ Growth Stocks to Buy for the Next 2 Years

3. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 12, Alnylam Pharmaceuticals reported its earnings for 2025, with nearly $3 billion in total revenue, which was an 81% increase year-over-year. Q4 was particularly strong, with net product revenue reaching $995 million, fueled by a 151% year-over-year surge in the TTR franchise following the successful launch of Amphotra for ATTR cardiomyopathy.

In this quarter, Alnylam also launched Cyreli, which is a new RNAi manufacturing platform designed to expand capacity and reduce long-term costs. Looking ahead to 2026, the company issued optimistic guidance, forecasting combined net product sales between $4.9 billion and $5.3 billion, despite anticipating a modest mid-single-digit decrease in net pricing for its core products.

Leadership emphasized the strength of Alnylam Pharmaceuticals Inc.’s (NASDAQ:ALNY) internal pipeline, which includes over 25 active clinical programs. Executives also highlighted the potency of the company’s ACVR1C asset in the obesity space and the long-term potential for products like Nrierran to drive operating margins into the mid-40s by 2030.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the US, Europe, and internationally.